Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip  Tetra) in South Korea

ConclusionThis post-marketing surveillance study confirms that QIV is well tolerated and has an acceptable safety profile in routine practice in South Korea. No unexpected safety concerns were identified.Trial RegistrationClinicalTrials.gov identifier NCT05406180.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research